C Niedworok1, H Rübben2. 1. Klinik für Urologie und Kinderurologie, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Deutschland. christian.niedworok@uk-essen.de. 2. Klinik für Urologie und Kinderurologie, Universitätsklinikum Essen, Universität Duisburg-Essen, Hufelandstr. 55, 45122, Essen, Deutschland.
Abstract
BACKGROUND: Patients with metastatic urothelial carcinoma have a poor prognosis. Standard of care is a systemic chemotherapy but surgical excision of metastasis can be performed in individual approaches. OBJECTIVES: To evaluate treatment options and study results and to identify and discuss advantages and disadvantages of metastasectomy in urothelial carcinoma. MATERIALS AND METHODS: Database analysis and discussion of clinical trials concerning metastasectomy in urothelial carcinoma. RESULTS: In individual cases, metastasectomy can be a reasonable additional therapeutic approach to systemic chemotherapy. Especially patients suffering from symptomatic metastatic disease benefit from extended surgical effort but further effects on survival cannot be expected. CONCLUSIONS: Patients undergoing metastasetomy should be well selected concerning general physical condition. Metastasectomy in urothelial carcinoma remains an individual therapeutic approach and should be performed in combination with systemic chemotherapy.
BACKGROUND:Patients with metastatic urothelial carcinoma have a poor prognosis. Standard of care is a systemic chemotherapy but surgical excision of metastasis can be performed in individual approaches. OBJECTIVES: To evaluate treatment options and study results and to identify and discuss advantages and disadvantages of metastasectomy in urothelial carcinoma. MATERIALS AND METHODS: Database analysis and discussion of clinical trials concerning metastasectomy in urothelial carcinoma. RESULTS: In individual cases, metastasectomy can be a reasonable additional therapeutic approach to systemic chemotherapy. Especially patients suffering from symptomatic metastatic disease benefit from extended surgical effort but further effects on survival cannot be expected. CONCLUSIONS:Patients undergoing metastasetomy should be well selected concerning general physical condition. Metastasectomy in urothelial carcinoma remains an individual therapeutic approach and should be performed in combination with systemic chemotherapy.
Authors: Arlene O Siefker-Radtke; Garrett L Walsh; Louis L Pisters; Yu Shen; David A Swanson; Christopher J Logothetis; Randall E Millikan Journal: J Urol Date: 2004-01 Impact factor: 7.450
Authors: Stephen A Boorjian; Matthew K Tollefson; John C Cheville; Brian A Costello; Prabin Thapa; Igor Frank Journal: J Urol Date: 2011-09-25 Impact factor: 7.450
Authors: C N Sternberg; P de Mulder; J H Schornagel; C Theodore; S D Fossa; A T van Oosterom; J A Witjes; M Spina; C J van Groeningen; B Duclos; J T Roberts; C de Balincourt; L Collette Journal: Eur J Cancer Date: 2005-12-05 Impact factor: 9.162
Authors: Paul Sweeney; Randall Millikan; Machelle Donat; Christopher G Wood; Arlene Siefker Radtke; Curtis A Pettaway; H Barton Grossman; Colin P N Dinney; David A Swanson; Louis L Pisters Journal: J Urol Date: 2003-06 Impact factor: 7.450
Authors: J Alfred Witjes; Eva Compérat; Nigel C Cowan; Maria De Santis; Georgios Gakis; Thierry Lebret; Maria J Ribal; Antoine G Van der Heijden; Amir Sherif Journal: Eur Urol Date: 2013-12-12 Impact factor: 20.096